Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EBT (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBT for 15 consecutive years, with -$4.4 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 17.01% to -$4.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$13.9 million, a 4.28% increase, with the full-year FY2024 number at -$14.6 million, down 9.65% from a year prior.
  • EBT was -$4.4 million for Q3 2025 at Plus Therapeutics, down from -$1.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$1.5 million in Q2 2023 to a low of -$5.6 million in Q4 2022.
  • A 5-year average of -$3.8 million and a median of -$3.8 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: soared 72.04% in 2023, then plummeted 146.76% in 2024.
  • Plus Therapeutics' EBT stood at -$3.7 million in 2021, then crashed by 52.87% to -$5.6 million in 2022, then surged by 31.93% to -$3.8 million in 2023, then decreased by 1.53% to -$3.9 million in 2024, then fell by 13.32% to -$4.4 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EBT are -$4.4 million (Q3 2025), -$1.5 million (Q2 2025), and -$4.1 million (Q1 2025).